Scientists have identified a novel strategy to combat treatment-resistant cancers by targeting genetic mutations that enable tumors to survive therapy. Researchers developed a computational tool, SpotNeoMet, to detect shared resistance-related mutations in cancer cells. These mutations produce neo-antigens, unique protein fragments found only on cancer cells, which can be targeted by new immunotherapies designed to train the immune system to attack these resistant cells. The approach was tested in metastatic prostate cancer.